ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield Platform

We recently published 10 Best Biotech Stocks to Buy Under $10. ImmunityBio, Inc. is among them.

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation immunotherapies and cell therapies to treat cancer and infectious diseases, and is among the best biotech stocks. Its lead product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer (NMIBC), designed to activate NK cells, T cells, and memory T cells for durable disease control.

In June 2025, the FDA granted Expanded Access authorization for ImmunityBio, Inc. (NASDAQ:IBRX)’s Cancer BioShield™ platform, anchored by ANKTIVA, to treat lymphopenia in patients with relapsed or refractory solid tumors. These patients typically have critically low lymphocyte counts after standard treatments like chemotherapy or radiation. Data presented at the 2025 ASCO Annual Meeting showed that restoring lymphocytes in this group significantly prolongs survival, highlighting the company’s potential to address one of the most dangerous side effects of cancer therapy.

The business is also broadening its pipeline. In August 2025, it launched a Phase 2 trial of ANKTIVA for Long COVID, exploring immune modulation for post-infectious chronic disease. Additionally, the corporation initiated ResQ201A, a randomized trial combining N-803 (an interleukin-15 superagonist) with a PD-1 inhibitor for second-line non-small cell lung cancer, with plans for global expansion.

For papillary-only NMIBC, the FDA previously issued a Refuse-to-File letter on a supplemental BLA, but ImmunityBio, Inc. (NASDAQ:IBRX) is resubmitting updated long-term trial data showing encouraging outcomes with ANKTIVA plus BCG. The company is also engaging with regulators to update clinical guidelines that could expand access for more bladder cancer patients.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.